Undiscovered Gems in India to Explore This October 2024 #IndiaFinance
CashNews.co
Over the last 7 days, the Indian market has experienced a 4.2% decline, yet it remains up by an impressive 40% over the past year with earnings forecasted to grow by 18% annually. In this dynamic environment, identifying stocks that combine strong growth potential with resilience can uncover undiscovered gems worth exploring.
Name
Debt To Equity
Revenue Growth
Earnings Growth
Health Rating
Bharat Rasayan
8.15%
0.10%
-7.93%
★★★★★★
Indo Amines
82.32%
17.15%
19.98%
★★★★★☆
Wealth First Portfolio Managers
4.08%
-43.42%
42.63%
★★★★★☆
Master Trust
37.05%
27.64%
41.99%
★★★★★☆
Indo Tech Transformers
2.30%
22.05%
60.31%
★★★★★☆
Piccadily Agro Industries
50.57%
13.86%
42.85%
★★★★★☆
Genesys International
12.13%
15.75%
36.33%
★★★★★☆
Insolation Energy
88.64%
163.87%
419.31%
★★★★★☆
Monarch Networth Capital
32.66%
31.02%
50.24%
★★★★☆☆
Sky Gold
135.31%
22.02%
48.03%
★★★★☆☆
Click here to see the full list of 456 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.
Let’s dive into some prime choices out of from the screener.
Simply Wall St Value Rating: ★★★★★☆
Overview: Aarti Pharmalabs Limited, along with its subsidiaries, is involved in the production and distribution of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives both domestically and globally, with a market capitalization of ₹56.27 billion.
Operations: Aarti Pharmalabs generates revenue primarily from its pharmaceuticals segment, amounting to ₹19.50 billion. The company’s financial performance is reflected in its net profit margin, which stands at 5.20%.
Aarti Pharmalabs, a smaller player in the pharmaceutical sector, showcases promising financial health with its net debt to equity ratio at 10.9%, indicating satisfactory leverage. The company’s earnings have surged by 35% annually over the past five years, though recent growth of 19.4% aligns with industry averages. A price-to-earnings ratio of 25x suggests it is valued attractively compared to the broader Indian market at 32.7x. Recent board changes bring seasoned professionals on board, potentially enhancing strategic direction and governance quality while declaring a dividend of INR 1 per share for FY2024 underscores its commitment to shareholder returns.
NSEI:AARTIPHARM Earnings and Revenue Growth as at Oct 2024
Simply Wall St Value Rating: ★★★★★★
Overview: CARE Ratings Limited is a credit rating agency offering diverse rating and related services both in India and internationally, with a market capitalization of ₹42.08 billion.
Operations: CARE Ratings generates revenue primarily through its credit rating services offered in India and internationally. The company’s net profit margin has shown a noteworthy trend, reflecting the efficiency of its operations.
CARE Ratings, a debt-free player in the Indian market, has shown stable growth with earnings increasing 1.9% annually over the past five years. Despite not outpacing the Capital Markets industry last year, its earnings rose by 29.2%. The company reported a significant jump in net income for Q2 2024 to ₹460.9 million from ₹351.74 million previously, alongside basic earnings per share of ₹15.41 compared to ₹11.83 last year. Additionally, CARE Ratings declared an interim dividend of ₹7 per share for FY2024-25, highlighting its commitment to shareholder returns amidst steady free cash flow generation like INR 817 million in March 2024 and INR 662 million recently in September 2024 despite fluctuations throughout the period.
NSEI:CARERATING Debt to Equity as at Oct 2024
Simply Wall St Value Rating: ★★★★☆☆
Overview: Paradeep Phosphates Limited is involved in the manufacture, trade, distribution, and sale of urea and complex fertilizers in India with a market capitalization of ₹73.81 billion.
Operations: Paradeep Phosphates generates revenue primarily from the sale of fertilizers and trading materials, amounting to ₹108.98 billion.
Paradeep Phosphates, a notable player in the Indian chemicals sector, has demonstrated impressive earnings growth of 85.4% over the past year, outpacing the industry’s 9.9%. Despite trading at a significant discount of 47.6% below its estimated fair value, challenges persist with a high net debt to equity ratio at 109.3%, and interest payments are not well covered by EBIT (1.9x coverage). Recent developments include resolving a long-standing tax dispute with an INR 1.912 million demand and resuming operations at its ammonia and urea plants after temporary shutdowns, signaling operational resilience amidst financial hurdles.
NSEI:PARADEEP Debt to Equity as at Oct 2024
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NSEI:AARTIPHARM NSEI:CARERATING and NSEI:PARADEEP.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
